Novartis and a consortium of life sciences companies have collaborated with Bill & Melinda Gates Foundation (BMGF) to advance the development, manufacture and delivery of vaccines, diagnostics and treatments for COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
The Covid-19 pandemic has shined a bright light on the need to manage patients remotely wherever possible.
Xencor and Vir Biotechnology have entered into a technology licence agreement for the use of Xtend XmAb Fc technology in investigational antibodies for the treatment of COVID-19, the disease resulted due to the novel coronavirus SARS-CoV-2.
Design Therapeutics announced today that it is launching to create and develop a new class of therapies for patients with serious degenerative disorders caused by nucleotide repeat expansions.
Healthcare biotechnology company Entos Pharmaceuticals has unveiled plans to develop a Fusogenix DNA vaccine for the prevention of COVID-19 infections.
RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar; hereinafter "the Territory").
Pfizer has collaborated with Biopharmaceutical New Technologies (BioNTech) for the co-development of a potential COVID-19 vaccine.
AcelRx Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the execution of a definitive merger agreement to acquire Tetraphase Pharmaceuticals, Inc. (Tetraphase) in a stock for stock deal at an exchange ratio of 0.6303 shares of AcelRx for each share of Tetraphase, or approximately $14.4 million as of the close of trading on March 13, 2020, plus a contingent value right (CVR).
BioStem Life Sciences, a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company") a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced the buildout of a brand new R&D lab.
Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, is entering into a collaborative research agreement with the Lewis Katz School of Medicine at Temple University, Philadelphia, USA.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.